Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793072 | 1.00 | BRD4 (0.43) | BRD4DYRK1APTGS2MTNR1AMTNR1B | |
| SCHEMBL25298101 | 0.88 | MTNR1A (0.41) | MTNR1AMTNR1BNQO2NPC1RAB9A | |
| SCHEMBL30565976 | 0.82 | ALDH1A1 (0.33) | BRD4PTGS2MTNR1AMTNR1BKDM4E | |
| SCHEMBL25249736 | 0.82 | ALDH1A1 (0.33) | BRD4PTGS2MTNR1AMTNR1BKDM4E | |
| SCHEMBL25254239 | 0.79 | ADRB2 (0.43) | NPC1 | |
| SCHEMBL25247836 | 0.76 | HTR1A (0.40) | NQO2KDM4E | |
| SCHEMBL30565933 | 0.76 | HTR1A (0.40) | NQO2KDM4E | |
| SCHEMBL30565949 | 0.75 | HTR2A (0.42) | — | |
| SCHEMBL25248599 | 0.75 | HTR2A (0.42) | — | |
| SCHEMBL25293730 | 0.75 | HTR6 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| US-20250163044-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-05-22 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| EP-4452979-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | BRD4 1783/4885DYRK1A 3108/4885PTGS2 2106/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | BRD4 1783/4885DYRK1A 3108/4885PTGS2 2106/4885 |
| US-20250163044-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | BRD4 1783/4885DYRK1A 3108/4885PTGS2 2106/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | BRD4 1783/4885DYRK1A 3108/4885PTGS2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.